Protein therapeutics market overview and analysis by type, application, protein function, end user- forecast to 2030. Global Protein Therapeutics Market is expected to cross USD 289.74 billion by 2030 at a CAGR of 6.86%. Protein therapeutics are treatments based on proteins created synthetically. They are strong, fast-acting drugs that give the body a specific amount of tiny protein molecules. Monoclonal antibodies, insulin, fusion proteins, erythropoietin, interferon, human growth hormones (HGH), and follicle-stimulating hormones are examples of recombinant proteins that are copies of naturally occurring proteins. Haematological, hormonal, and immunological disorders, cancer, diabetes, and genetic anomalies are a few of the conditions they help address. Protein treatments that are given intravenously, orally, or through a mix of these routes, are also employed.
The rise in the prevalence of chronic diseases such metabolic, immunologic, and haematological problems is to blame for the rise in hospital admissions. The prevalence of chronic diseases, which is fueling the market’s growth, is directly tied to the increased demand for protein therapies. Because of this, the market is growing as more people become aware of the advantages of protein treatments, such as their high efficacy and minimal risk of adverse effects. The growing acceptability of plasma-derived therapies and increased consumer knowledge of protein’s high efficacy are other factors driving the market forward over the forecast period. Increased interest in protein therapeutics is anticipated to drive growth in the global market over the forecast period. Rapid technological advancements in the area of protein treatments are anticipated to positively affect demand. The expanding number of government initiatives to support the healthcare industry are probably going to foster favourable market growth circumstances.
During the projected period, however, the high cost of protein treatments and unfavorable reimbursement are likely to restrain market expansion. Adoption of protein therapies for novel indications, on the other hand, is expected to generate attractive opportunities for market players, as well as the untapped potential of developing countries. The unexpected outbreak of the coronavirus illness (COVID-19) is giving market players with even more potential opportunities.
Abbott Laboratories (US), Amgen Inc. (US), Baxter International Inc. (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd. (Switzerland), Johnson & Johnson (US), Merck & Co., Inc. (US), Novo Nordisk A/S (Denmark), CSL Behring (US), Bristol Myers Squibb Co. (US), Pfizer Inc. (US), Sanofi (France), and Biogen, Inc. (US).
The protein therapeutics market size has been divided into three categories: type, application, and end user.
Monoclonal antibodies, insulin, fusion proteins, erythropoietin, interferon, human growth hormone, follicle-stimulating hormone, and others are among the products available. Because of the rising prevalence of diabetes around the world, the insulin segment is the fastest-growing. Because insulin is widely utilized in the treatment of diabetes, demand for protein therapies is expected to rise during the forecast period.
The worldwide protein therapies market has been divided into cancer, metabolic diseases, immunologic disorders, hematological disorders, and others based on application. Because of the increased frequency of cancer around the world, the cancer segment accounts for a substantial portion of the worldwide protein therapies market. During the forecast period, it is likely to promote market growth.
The global protein therapies market has been divided into hospitals and clinics, specialty centers, and others based on the end user. During the projected period, the hospitals and clinics segment is expected to develop due to an increase in hospital admissions and the increased prevalence of chronic diseases.
In the protein therapies industry, North America had the greatest revenue. The demand for therapeutic proteins is expanding as a result of increased government initiatives and growing concerns about healthcare workers’ health and safety. In addition, one of the primary reasons driving market growth over the projection period is the increased prevalence of cancer.
During the forecast period, the western European healthcare market, which includes Germany, the United Kingdom, France, and Italy, is expected to see an increase in healthcare expenditure, as well as an increase in cases of rheumatoid arthritis, multiple sclerosis, and chronic inflammatory demyelinating polyneuropathy, resulting in the growth of the protein therapeutics market
The fastest-growing geographical market is Asia-Pacific. Emerging market participants in previously untouched regions, increased R&D in the protein therapeutics segment, the government’s increased focus on immunization to avoid various diseases, and a large target population are all factors impacting market expansion. One of the primary factors driving market expansion in the region is the expanding elderly population.
Government initiatives and increased investments in the healthcare sector of the UAE and South Africa are likely to boost market expansion in the Middle East and Africa.
About Market Research Future:
Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.
Market Research Future (Part of Wantstats Research and Media Private Limited)
99 Hudson Street, 5Th Floor
New York, NY 10013
United States of America
+1 628 258 0071 (US)
+44 2035 002 764 (UK)